Posted on Leave a comment

Profit before Tax up 36% to Rs 406 crores for the quarter

Net Profit up 35% to Rs 333 crores

Vadodara, October 22nd, 2020

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30th September 2020.

Financial Highlights

  • Net Sales for the quarter up 17% to Rs 1457 crores from Rs. 1241 crores.
  • Net Profit for the quarter up 35% to Rs 333 crores from Rs 246 crores.
  • Net sales for H-1 FY21 up 28% to Rs 2798 crores against Rs 2190 crores.
  • Net profit for H-1 FY21 up 72% to Rs 635 crores from Rs 370 crores.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “It was a strong quarter for the company led by growth in the domestic business. The International as well as API Business also continued to perform well.”

Operational Highlights

International Business

  • International formulations grew 21% to Rs 779 crores in the quarter and 41% to Rs 1550 crores for H-1.
  • US Generics grew 8% to Rs 582 crores in the quarter and 33% to Rs 1177 Crores for H-1.
  • Ex-US International Formulations grew 84% to Rs 197 crores in the quarter and 73% to Rs 373 Crores for H-1.
  • 6 ANDA approvals received during the quarter; 131 Cumulative ANDA approvals.
  • 7 ANDA filings during the quarter; Cumulative ANDA filings at 198.

India Formulations Business

  • India formulations business grew 6% to Rs 415 crores in the quarter and was Rs 721 crores for H-1.

 

API Business

  • API business grew 29% to Rs 263 crores in the quarter and 40% to Rs 528 crores for H-1.
  • 2 DMF were filed in the quarter.

 

Summary of Total Revenue is as under:

                                        (Rs in Crores)

Particulars Q2 FY21 Q2 FY20 % Change H-1 FY21 H-1 FY19 % Change
Formulation
  USA

Ex- US

582

197

539

107

8%

84%

1177

373

883

216

33%

73%

  India 415 391 6% 721 715 1%
API 263 204 29% 528 376 40%
Total 1457 1241 17% 2798 2190 28%

Summary of Profit is as under:                                                        (Rs in Crores)

Particulars Q2 FY21 Q2 FY20 % Change H1 FY21 H1 FY20 % Change
EBITDA Pre R&D 628 505 24% 1177 836 41%
EBITDA Pre R&D % 43% 41%   42% 38%  
EBITDA Post R&D 455 342 33% 871 542 61%
EBITDA Post R&D % 31% 28%   31% 25%  
Profit Before Tax 406 299 36% 775 458 69%
Net Profit after Tax 333 246 35% 635 370 72%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at   www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

Leave a Reply

Your email address will not be published.